Koselugo under the microscope: Real-World data on nerve tumor drug
NCT ID NCT06360406
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 4 times
Summary
This study tracks how well the drug Koselugo (selumetinib) works and what side effects it causes in people with Neurofibromatosis Type 1 and painful nerve tumors. About 200 patients in South Korea will be followed during their normal doctor visits. The goal is to confirm the drug's safety and effectiveness in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMA, PLEXIFORM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGBusan, South Korea
-
Research Site
RECRUITINGChungcheongbuk-do, South Korea
-
Research Site
RECRUITINGDaejeon, South Korea
-
Research Site
RECRUITINGGyeonggi-do, South Korea
-
Research Site
RECRUITINGIncheon, South Korea
-
Research Site
RECRUITINGJeonnam, South Korea
-
Research Site
SUSPENDEDSeoul, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
COMPLETEDSeoul, South Korea
-
Research Site
NOT_YET_RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGWŏnju, South Korea
-
Research Site
RECRUITINGYangsan, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Light-Activated cream could slow growth of NF1 skin tumors
- Antioxidant drug shows promise for kids with NF1
- New drug combo shows promise for rare nerve tumors
- Could a common supplement help kids with NF1 learn and move better?
- New drug combo aims to tame rare childhood leukemia
- New stem cell transplant aims to cut dangerous side effects in blood cancer patients